JP Patent

JP2008303145A — Ｇｒｋ阻害剤からなる強心薬

Assigned to Takeda Pharmaceutical Co Ltd · Expires 2008-12-18 · 17y expired

What this patent protects

【課題】新規な強心薬の提供。【解決手段】G protein-coupled receptor kinase（Ｇ蛋白共役型受容体リン酸化酵素；GRK）阻害作用を有する化合物もしくはそのプロドラッグ、またはその塩（GRK阻害剤）を含有してなる強心薬。【選択図】なし

USPTO Abstract

【課題】新規な強心薬の提供。【解決手段】G protein-coupled receptor kinase（Ｇ蛋白共役型受容体リン酸化酵素；GRK）阻害作用を有する化合物もしくはそのプロドラッグ、またはその塩（GRK阻害剤）を含有してなる強心薬。【選択図】なし

Drugs covered by this patent

elacestrant-hydrochloride (ELACESTRANT HYDROCHLORIDE)

Patent Metadata

Patent number: JP2008303145A
Jurisdiction: JP
Classification: —
Expires: 2008-12-18
Drug substance claim: No
Drug product claim: No
Assignee: Takeda Pharmaceutical Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.